Joe Nabhan
Chief Scientific Officer K2B Therapeutics Inc.
Joe Nabhan is Chief Scientific Officer at K2B Therapeutics, where he leads discovery and translational research focused on developing next-generation targeted therapeutics to treat cancer. Before joining K2B, he served as CSO of Vesigen Therapeutics, advancing a novel platform for the delivery of genome editors and RNA cargoes. Previously, at Astellas Pharma, he built a drug-discovery portfolio spanning multiple modalities as head of RNA biology, and at Pfizer, he directed the Repeat Expansion Disease group investigating therapeutic strategies for multiple disorders. He began his career in industry at Millennium Takeda, working on small-molecule programs targeting protein-homeostasis pathways in cancer. Joe holds a PhD from McGill University.
Seminars
- Engineering a CD47 ligand as a selective tumor-targeting moiety
- Demonstrating potent in vitro and in vivo efficacy of KBA651 across diverse cancer models
- Evaluating pharmacokinetics and safety to support translational studies
- Discussing the impact of small format conjugates on PK profiles
- Discussing how linker selection can impact the overall performance of small format conjugates
- Highlighting their potential vs their pitfalls for tumor types which are resistant to ADCs
